Menu
Annual · values202520242023
Operating Cash Flow-3.44 M USD-3.96 M USD81000 USD
Depreciation & Amortization
Stock-Based Compensation
Capital Expenditures
Cash Flow from Investing
Cash Flow from Financing6.66 M USD5.13 M USD-425000 USD
Dividends Paid
Stock Buybacks
Free Cash Flow

Kairos Pharma Ltd. is a pharmaceutical company focused on the research, development, and commercialization of innovative therapies. Its primary function is to advance treatments that target niche, unmet medical needs, particularly in the fields of oncology and degenerative diseases. The company is committed to harnessing cutting-edge scientific advancements and biotechnology, working alongside healthcare professionals and researchers to bring viable solutions to the market. Notable features include its robust pipeline of clinical trials that explore novel drug candidates and proprietary platforms aimed at improving patient outcomes. Kairos Pharma Ltd. plays a pivotal role in the healthcare sector, contributing to the development of new medications that offer hope to patients and healthcare providers alike. By addressing specialized medical demands, the company influences the pharmaceutical landscape and supports the ongoing evolution of targeted therapies.